Key terms

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ACAD news

Apr 09 6:40am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD) by TipRanks Apr 08 10:40pm ET Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD) by TipRanks Apr 01 8:46am ET Largest borrow rate increases among liquid names by TipRanks Mar 25 8:48am ET Acadia Pharmaceuticals price target lowered to $25 from $29 at JPMorgan by TipRanks Mar 15 11:32am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Mar 14 11:01am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Mar 13 8:46am ET Acadia Pharmaceuticals price target lowered to $30 from $40 at Morgan Stanley by TipRanks Mar 12 9:51am ET Oracle, Dollar General upgraded: Wall Street’s top analyst calls by TipRanks Mar 12 9:23am ET Acadia Pharmaceuticals price target lowered to $32 from $36 at Needham by TipRanks Mar 12 9:18am ET Acadia Pharmaceuticals price target lowered to $30 from $35 at RBC Capital by TipRanks Mar 12 8:40am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), AbbVie (ABBV) and ACADIA Pharmaceuticals (ACAD) by TipRanks Mar 12 7:43am ET Acadia Pharmaceuticals price target lowered to $19 from $25 at Oppenheimer by TipRanks Mar 12 6:46am ET Acadia Pharmaceuticals price target lowered to $31 from $40 at Baird by TipRanks Mar 12 6:35am ET Acadia Pharmaceuticals price target lowered to $30 from $33 at BofA by TipRanks Mar 12 6:30am ET Analysts Are Bullish on Top Healthcare Stocks: ACELYRIN, INC. (SLRN), ZyVersa Therapeutics (ZVSA) by TipRanks Mar 12 6:22am ET Acadia Pharmaceuticals price target lowered to $33 from $40 at Canaccord by TipRanks Mar 12 6:16am ET Acadia Pharmaceuticals price target lowered to $39 from $44 at JMP Securities by TipRanks Mar 12 5:55am ET ACADIA Pharmaceuticals Maintains Buy Rating Despite Price Target Adjustment by TipRanks Mar 12 5:49am ET Acadia (NASDAQ:ACAD) Plunges as Pimavanserin Disappoints in Phase 3 Trial by TipRanks Mar 12 5:37am ET Acadia Pharmaceuticals price target lowered to $30.19 from $38 at Citi by TipRanks Mar 12 5:20am ET Maintaining Hold on ACADIA Pharmaceuticals Amid Clinical Setbacks and Valuation Adjustments by TipRanks Mar 12 4:45am ET Acadia Pharmaceuticals downgraded to Neutral from Buy at Mizuho by TipRanks Mar 12 4:41am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Legend Biotech (LEGN), ACADIA Pharmaceuticals (ACAD) and CytomX Therapeutics (CTMX) by TipRanks Mar 12 12:40am ET Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Larimar Therapeutics (LRMR) by TipRanks Mar 11 4:36pm ET Acadia Pharmaceuticals falls 20% to $19.32 after resumption of trade by TipRanks Mar 11 4:35pm ET Acadia trading resumes by TipRanks Mar 11 4:17pm ET Acadia Pharmaceuticals to resume trading at 4:35pm ET by TipRanks Mar 11 4:13pm ET Acadia Pharmaceuticals says phase 3 Pimavanserin study did not meet endpoint by TipRanks Mar 11 4:00pm ET Acadia trading halted, news pending by TipRanks Mar 11 1:20am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD) and Enhabit, Inc (EHAB) by TipRanks Mar 08 7:26am ET RBC Capital Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD) by TipRanks

No recent news articles are available for ACAD

Mar 27 10:37am ET Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Acadia Pharmaceuticals Inc. (ACAD) Investigation by Newsfile Mar 19 8:50am ET Grabar Law Office Investigates Claims on Behalf of Shareholders of Acadia Pharmaceuticals Inc. (ACAD) by Newsfile Mar 13 3:22pm ET Grabar Law Office Investigates Claims on Behalf of Shareholders of Acadia Pharmaceuticals Inc. (ACAD) by Newsfile Mar 13 7:04am ET INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm by Newsfile Mar 12 7:02am ET INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm by Newsfile

ACAD Financials

1-year income & revenue

Key terms

ACAD Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ACAD Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Donald Trump might no longer own a majority of TMTG after a new public share offering.
Joe Raedle/Getty Images
Trump stock tanks after announcing massive share sale
1040 US Individual Income Tax Return Form
Nora Carol Photography/Moment RF/Getty Images
Three ways investors can minimize their tax payments
People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.
Spencer Platt/Getty Images
Dow closes nearly 500 points lower on fears of potential Iranian attack on Israel
JPMorgan beat earnings expectations this Friday, unofficially kicking off the first quarter earnings season.
Win McNamee/Getty Images
Jamie Dimon says chance of a bad economy is ‘higher than other people think’